

WHAT IS CLAIMED IS:

1. An isolated mammalian polypeptide comprising the sequence of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 9, SEQ ID NO: 13, SEQ ID NO: 17, SEQ ID NO: 21, SEQ ID NO: 23, SEQ ID NO: 25, SEQ ID NO: 27 or SEQ ID NO: 29, or variant polypeptides corresponding to SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 9, SEQ ID NO: 13, SEQ ID NO: 17, SEQ ID NO: 21, SEQ ID NO: 23, SEQ ID NO: 25, SEQ ID NO: 27 or SEQ ID NO: 29, in which one or more amino acids are replaced, deleted, inserted and/or added.

2. An isolated mammalian polypeptide comprising the sequence of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 10, SEQ ID NO: 14, SEQ ID NO: 18, SEQ ID NO: 22, SEQ ID NO: 24, SEQ ID NO: 26, SEQ ID NO: 28 or SEQ ID NO: 30, or variant polypeptides corresponding to SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 10 or SEQ ID NO: 14, SEQ ID NO: 18, SEQ ID NO: 22, SEQ ID NO: 24, SEQ ID NO: 26, SEQ ID NO: 28 or SEQ ID NO: 30, in which one or more amino acids are replaced, deleted, inserted and/or added.

3. An isolated mammalian polypeptide encoded by the nucleic acid sequence of SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 11, SEQ ID NO: 15 or SEQ ID NO: 19, or variant nucleic acids that encode for variant polypeptides corresponding to SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 9, SEQ ID NO: 13 or SEQ ID NO: 17, in which one or more amino acids are replaced, deleted, inserted and/or added.

4. An isolated mammalian polypeptide encoded by the nucleic acid sequence of SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 12, SEQ ID NO: 16 or SEQ ID NO: 20, or variant nucleic acids that encode for variant polypeptides corresponding to SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 10, SEQ ID NO: 14 or SEQ ID NO: 18, in which one or more amino acids are replaced, deleted, inserted and/or added.

5. A pharmaceutical composition comprising one or more mature polypeptides of SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29 or SEQ ID NO: 30, or variant mature polypeptides corresponding to SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29 or SEQ ID NO: 30, in which one or more amino acids are replaced, deleted, inserted and/or added, wherein the polypeptide is an active agent in the pharmaceutical composition.

6. A vector comprising the nucleic acid sequence of SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 19 or SEQ ID NO: 20, or variant nucleic acids that encode for variant polypeptides corresponding to SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 9 or SEQ ID NO: 10, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 17 or SEQ ID NO: 18, in which one or more amino acids are replaced, deleted, inserted and/or added.

7. A pharmaceutical composition comprising one or more polypeptides encoded for by SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 19 or SEQ ID NO: 20, or encoded for by variant nucleic acids that encode for variant polypeptides corresponding to SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 9 or SEQ ID NO: 10, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29 or SEQ ID NO: 30, in which one or more amino acids are replaced, deleted, inserted and/or added.

8. An isolated antibody comprising an antigenic polypeptide that binds to a specific portion of a polypeptide sequence of claim 1 or 2.

9. A kit comprising one or more polypeptides of claim 1 or 2, wherein the kit comprises:

- a) instructional material for the one or more polypeptides; or
- b) one or more containers into which the one or more polypeptides are segregated.

10. A method of producing one or more polypeptides, the method comprising:

- a) culturing transformed cells comprising one or more vectors of claim 6; and
- b) isolating the one or more polypeptides.

11. A method of screening for a compound that binds to a polypeptide, the method comprising:

- a) contacting one or more test compounds with a polypeptide of claim 1 or 2;
- b) determining whether a test compound binds to the polypeptide; and
- c) selecting the test compound that binds to the polypeptide.

12. A method of screening for a polypeptide that binds to a cell, the method comprising:
- a) contacting a polypeptide of claim 1 or 2 with a cell; and
 - b) determining whether the polypeptide binds to the cell.

13. The method of claim 12, wherein the cell is a hematopoietic cell.

14. The method of claim 12, wherein the cell is a neuronal cell.

15. The method of claim 13, wherein the hematopoietic cell is a progenitor or stem cell.

16. The polypeptides of claim 1 or 2, wherein the polypeptides are modified.

17. The polypeptides of claim 16, wherein the polypeptides are lipid modified.

18. The polypeptides of claim 16, wherein the polypeptides are glycosylated.

19. The polypeptides of claim 16, wherein the polypeptides are modified by acylation.

20. A method of modulating the physiology of a cell type, the method comprising:

- a) contacting the cell type with a polypeptide of claim 1 or 2; and

- b) monitoring the cell type for a change in physiology.

21. An isolated mammalian nucleic acid comprising the sequence of SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 19 or SEQ ID NO: 20, or variant nucleic acids that encode for variant polypeptides corresponding to SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 9, SEQ ID NO: 13, SEQ ID NO: 17, SEQ ID NO: 21, SEQ ID NO: 23, SEQ ID NO: 25, SEQ ID NO: 27, SEQ ID NO: 29, SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 10, SEQ ID NO: 14, SEQ ID NO: 18, SEQ ID NO: 22, SEQ ID NO: 24, SEQ ID NO: 26, SEQ ID NO: 28 or SEQ ID NO: 30, in which one or more amino acids are replaced, deleted, inserted and/or added.

22. A binding partner comprising:

- a molecule that binds to a polypeptide of claim 1 or 2 with a K_d of approximately $10^{-8}M$ or greater or binds to a nucleic acid of claim 3, 4 or 21 with a K_d of approximately $10^{-8}M$ or greater.

23. An interference molecule comprising:

- a RNAi molecule generated to interfere with the protein expression of a polypeptide of claim 1 or 2.

24. An aptamer molecule comprising:

a nucleic acid molecule generated to specifically bind to a portion of a polypeptide of claim 1 or 2.

5

10

15

20

25

30

35

40

45